
Initiator Pharma Q1 - Slow and steady

Redeye provides a research update following the Q1 report recently published by Initiator Pharma. While the company is still awaiting a licensing deal with pudafensine before engaging in further clinical activities, Initiator maintains a very low cash burn. As we have previously stated, the company's full priority ahead is business development efforts as Initiator continues its pursuit of a licensing partner.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Initiator Pharma Q1 - Slow and steady